Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04768881
Title Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Newly Diagnosed or Recurrent Advanced Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics Inc
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
UCLA Los Angeles California 90095 United States Details
TOI Clinical Research Pasadena California 91105 United States Details
BRCR Global Plantation Florida 33322 United States Details
Minnesota Oncology Hematology Minneapolis Minnesota 55404 United States Details
Great Plains Health North Platte Nebraska 69101 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901 United States Details
New York Oncology Hematology Albany New York 12206 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
OH Care Clinical Trials Cincinnati Ohio 45242 United States Details
Cleveland Clinic Foundation Cleveland Ohio 44144 United States Details
Texas Oncology-Austin Central Austin Texas 78731 United States Details
Texas Oncology - Baylor Sammons Center Dallas Texas 75246 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field